Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability

R. C. Zangar, N. Bollinger, S. Verma, N. J. Karin and Y. Lu
Molecular Pharmacology June 2008, 73 (6) 1652-1658; DOI: https://doi.org/10.1124/mol.107.043976
R. C. Zangar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Bollinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Verma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. J. Karin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Lu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We have previously observed that CYP3A4 protein levels are suppressed by inhibition of the proteasome in primary cultured hepatocytes. Because this result is opposite of what would be expected if CYP3A4 were degraded by the proteasome, it seemed likely that there might be another protein susceptible to proteasomal degradation that regulated CYP3A4 expression. In this study, we evaluated whether the nuclear factor-κB (NF-κB) pathway was involved in that process. Our model system used an adenovirus system to express CYP3A4 protein in HepG2 cells, which are derived from human cancer cells. Similar to results in primary hepatocytes, the inhibition of the proteasome with N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) suppresses CYP3A4 protein levels. We also found that MG132 treatment had a broad affect on the NF-κB pathway, including down-regulation of NF-κB DNA binding activity and IκB kinase (IKK)α levels and up-regulation of IKKβ and inhibitory κB levels. Treatment of the HepG2 cells with several structurally distinct NF-κB inhibitors also suppressed CYP3A4 protein levels. When the HepG2 cells were treated with cycloheximide, a general inhibitor of protein synthesis, the loss of CYP3A4 protein was accelerated by cotreatment with either proteasome or NF-κB inhibitors. These results indicate that NF-κB activity regulated CYP3A4 protein stability, and they suggest that the NF-κB pathway was responsible for the decrease in CYP3A4 protein levels that resulted from the proteasomal inhibition.

Footnotes

  • This work was supported by National Institutes of Health grant CA117378 and by the Environmental Biomarkers Initiative, which is a Laboratory Directed Research and Development Program at Pacific Northwest National Laboratory (PNNL). PNNL is operated by Battelle for the U.S. Department of Energy.

  • ABBREVIATIONS: P450, cytochrome P450; MG132, N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal; NF-κB, nuclear factor-κB; IκB, inhibitory κB; IKK, IκB kinase; NAI, nuclear factor-κB activation inhibitor; CAPE, caffeic acid phenethyl ester; MPPB, 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine; PBS, phosphate-buffered saline; Ad3A4, CYP3A4-expressing adenovirus; AdRed, cytochrome P450 reductase-expressing adenovirus; MOI, multiplicity of infection; ER, endoplasmic reticulum; DiOC6(3), 3,3′-dihexyloxacarbocyanine iodide; RT-PCR, reverse transcription-polymerase chain reaction; RSV, Rous sarcoma virus; CON, control.

    • Received November 29, 2007.
    • Accepted March 11, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 73 (6)
Molecular Pharmacology
Vol. 73, Issue 6
1 Jun 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability

R. C. Zangar, N. Bollinger, S. Verma, N. J. Karin and Y. Lu
Molecular Pharmacology June 1, 2008, 73 (6) 1652-1658; DOI: https://doi.org/10.1124/mol.107.043976

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

The Nuclear Factor-κB Pathway Regulates Cytochrome P450 3A4 Protein Stability

R. C. Zangar, N. Bollinger, S. Verma, N. J. Karin and Y. Lu
Molecular Pharmacology June 1, 2008, 73 (6) 1652-1658; DOI: https://doi.org/10.1124/mol.107.043976
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics